TABLE 1.

Summary of clinical trials of CED for malignant gliomas following adoption of the Stupp protocol in 2005

Authors & Year	Trial Phase	Agent Infused	WHO Grade & Type (no.)	Flow Rate (mL/hr)	Vol Infused (mL)	Duration	Catheter No.	PFS (wks)	Median OS (wks)
Vogelbaum et al., 2007	I	Cintredekin besudotox	III AO (1); IV GBM (21)	0.75	3	4 days	2–4	5–78	44 (5–113)
Kunwar et al., 2007	I	Cintredekin besudotox	III AA (3), AO (2); IV GBM (46)	0.75	3	4–6 days	1–3	NA	45.9
Kunwar et al., 2010	III	Cintredekin besudotox	IV GBM (296)	0.75	3	4 days	2–4	NA	45.3
Bogdahn et al., 2011	IIB	Trabedersen	III AA (42); IV GBM (103)	0.24	40	7 days	1	NA	66 (GBM 29.2, AA 158)
Bruce et al., 2011	IB	Topotecan	III high-grade gliomas* (6); IV GBM (10)	0.4	40	4.17 days	2	22	58
Desjardins et al., 2018	I	PVSRIPO	IV GBM (61)	0.5	3.25	6.5 hrs	1	NA	50

AA = anaplastic astrocytoma; AO = anaplastic oligodendroglioma; NA = not available.

^*Including anaplastic astrocytomas, anaplastic oligodendrogliomas, and anaplastic ependymomas.